Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 54, Issue 19, Pages 6691-6703Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm2005699
Keywords
-
Categories
Funding
- Danish Council for Independent Research\Technology and Production [09-070364]
- German Federal Ministry of Education and Research (BMBF)
Ask authors/readers for more resources
The free fatty acid receptor 1 (FFA1, also known as GPR40) enhances glucose-stimulated insulin secretion from pancreatic beta-cells and is recognized as an interesting new target for treatment of type 2 diabetes. Several series of selective FFA1 agonists are already known. Most of these are derived from free fatty acids (FFAs) or glitazones and are relatively lipophilic. Aiming for the development of potent, selective, and less lipophilic FFA1 agonists, the terminal phenyl of a known compound series was replaced by nitrogen containing heterocycles. This resulted in the identification of 37, a selective FFA1 agonist with potent activity on recombinant human FFA1 receptors and on the rat insulinoma cell line INS-1E, optimal lipophilicity, and excellent in vitro permeability and metabolic stability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available